Y Intercept Hong Kong Ltd Makes New $244,000 Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Y Intercept Hong Kong Ltd purchased a new stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 44,518 shares of the company’s stock, valued at approximately $244,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Xeris Biopharma by 1.7% during the fourth quarter. Vanguard Group Inc. now owns 7,899,063 shares of the company’s stock valued at $26,778,000 after buying an additional 133,738 shares during the period. Geode Capital Management LLC grew its position in shares of Xeris Biopharma by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 3,351,426 shares of the company’s stock valued at $11,364,000 after acquiring an additional 17,956 shares during the period. Renaissance Technologies LLC grew its position in shares of Xeris Biopharma by 31.3% during the 4th quarter. Renaissance Technologies LLC now owns 2,098,840 shares of the company’s stock valued at $7,115,000 after acquiring an additional 500,120 shares during the period. Millennium Management LLC increased its stake in shares of Xeris Biopharma by 34.8% in the 4th quarter. Millennium Management LLC now owns 1,948,552 shares of the company’s stock worth $6,606,000 after purchasing an additional 502,853 shares in the last quarter. Finally, Nuveen Asset Management LLC raised its holdings in Xeris Biopharma by 13.6% in the 4th quarter. Nuveen Asset Management LLC now owns 1,903,442 shares of the company’s stock worth $6,453,000 after purchasing an additional 228,380 shares during the period. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Wall Street Zen lowered Xeris Biopharma from a “buy” rating to a “hold” rating in a report on Thursday, May 22nd. Oppenheimer lifted their price objective on Xeris Biopharma from $6.00 to $7.00 and gave the company an “outperform” rating in a research report on Friday, May 9th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.25.

Xeris Biopharma Trading Up 2.6%

NASDAQ:XERS opened at $5.13 on Thursday. Xeris Biopharma Holdings, Inc. has a 12-month low of $2.10 and a 12-month high of $6.07. The stock has a 50-day moving average price of $4.83 and a 200 day moving average price of $4.45. The stock has a market capitalization of $802.23 million, a P/E ratio of -17.10 and a beta of 0.66.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. The business had revenue of $57.80 million for the quarter, compared to analysts’ expectations of $57.61 million. On average, research analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Kevin Mcculloch purchased 25,000 shares of the business’s stock in a transaction on Friday, June 13th. The stock was acquired at an average price of $4.38 per share, for a total transaction of $109,500.00. Following the acquisition, the insider directly owned 1,708,585 shares of the company’s stock, valued at $7,483,602.30. This represents a 1.48% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 6.47% of the stock is owned by corporate insiders.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.